Investor Overview

Webcast ImageWebcast
Stifel 2016 Healthcare Conference (Replay)
11/16/16 at 10:15 a.m. ET
Stifel 2016 Healthcare Conference
Wednesday, November 16, 2016 10:15 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Piper Jaffray 28th Annual Healthcare Conference  (Replay)
11/29/16 at 12:30 p.m. ET
Piper Jaffray 28th Annual Healthcare Conference
Tuesday, November 29, 2016 12:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Inotek Pharmaceuticals is a clinical-stage, publicly traded, biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye. Our common stock is listed on the NASDAQ Global Market under the symbol "ITEK."

Glaucoma is a disease of the eye that is typically characterized by structural evidence of optic nerve damage, vision loss and consistently elevated intraocular pressure, or IOP. Our lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic... 
More >>
ITEK (Common Stock) $6.80 Stock is Down 0.15 (2.16%)12/09/16 4:00 p.m. ET
Recent NewsMore >>
DateTitle 
Nov 10, 2016Inotek Pharmaceuticals Announces Participation at Upcoming Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 10, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that members of Inotek’s leadership team are scheduled to participate at the following investor conferences in November: Global Mizuho Investor Conference in New York City ... 
Printer Friendly Version
Nov 9, 2016Inotek Pharmaceuticals Corporation Reports Third Quarter 2016 Financial Results and Operational Highlights
LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 9, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the quarter ended September 30, 2016. “During the summer, we achieved on-time completion of enrollment of the ... 
Printer Friendly Version
Oct 7, 2016Inotek Pharmaceuticals to Present at the 2016 Ophthalmology Innovation Summit
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 7, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer of Inotek, will present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmolo... 
Printer Friendly Version
Sep 29, 2016Inotek Pharmaceuticals Appoints Timothy Barberich to Board of Directors
LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 29, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Timothy Barberich has been appointed to its Board of Directors. Mr. Barberich will serve as head of the Compensation Committee. Mr. Barberich founde... 
Printer Friendly Version
PresentationsMore >>
DateTitle
11/29/16
Download Documentation November 2016 Corporate Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.